189 related articles for article (PubMed ID: 26472316)
1. Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes.
Tekatli H; Senan S; Dahele M; Slotman BJ; Verbakel WF
Radiother Oncol; 2015 Oct; 117(1):64-70. PubMed ID: 26472316
[TBL] [Abstract][Full Text] [Related]
2. Circumferential or sectored beam arrangements for stereotactic body radiation therapy (SBRT) of primary lung tumors: effect on target and normal-structure dose-volume metrics.
Rosenberg MW; Kato CM; Carson KM; Matsunaga NM; Arao RF; Doss EJ; McCracken CL; Meng LZ; Chen Y; Laub WU; Fuss M; Tanyi JA
Med Dosim; 2013; 38(4):407-12. PubMed ID: 23810414
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
4. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
[TBL] [Abstract][Full Text] [Related]
8. A comparative planning study for lung SABR between tri-Co-60 magnetic resonance image guided radiation therapy system and volumetric modulated arc therapy.
Park JM; Park SY; Kim HJ; Wu HG; Carlson J; Kim JI
Radiother Oncol; 2016 Aug; 120(2):279-85. PubMed ID: 27401404
[TBL] [Abstract][Full Text] [Related]
9. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive dosimetric planning comparison for early-stage, non-small cell lung cancer with SABR: fixed-beam IMRT versus VMAT versus TomoTherapy.
Xhaferllari I; El-Sherif O; Gaede S
J Appl Clin Med Phys; 2016 Sep; 17(5):329-340. PubMed ID: 27685129
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
Li Q; Swanick CW; Allen PK; Gomez DR; Welsh JW; Liao Z; Balter PA; Chang JY
Radiother Oncol; 2014 Aug; 112(2):256-61. PubMed ID: 25108807
[TBL] [Abstract][Full Text] [Related]
12. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm.
Latifi K; Oliver J; Baker R; Dilling TJ; Stevens CW; Kim J; Yue B; Demarco M; Zhang GG; Moros EG; Feygelman V
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1108-13. PubMed ID: 24529716
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.
Murray L; Ramasamy S; Lilley J; Snee M; Clarke K; Musunuru HB; Needham A; Turner R; Sangha V; Flatley M; Franks K
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):4-12. PubMed ID: 26474546
[TBL] [Abstract][Full Text] [Related]
15. Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy.
Tekatli H; Tetar SU; Nguyen TK; Warner A; Verbakel WF; Palma DA; Dahele M; Gaede S; Haasbeek C; Spoelstra FO; de Haan PF; Slotman BJ; Senan S
Acta Oncol; 2017 Apr; 56(4):548-554. PubMed ID: 28358667
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
17. Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema.
Binkley MS; Shrager JB; Leung AN; Popat R; Trakul N; Atwood TF; Chaudhuri A; Maxim PG; Diehn M; Loo BW
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):216-23. PubMed ID: 25015205
[TBL] [Abstract][Full Text] [Related]
18. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours.
Lenglet A; Campeau MP; Mathieu D; Bahig H; Lambert L; Vu T; Roberge D; Bilodeau L; Filion E
Radiother Oncol; 2019 May; 134():178-184. PubMed ID: 31005213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
